Efficacy and Safety of Taeeumjowi-tang in Obese Korean Adults: A Double-Blind, Randomized, and Placebo-Controlled Pilot Trial

Table 2

Analyses of anthropometric parameters.

Secondary outcomes (Anthropometric parameters)	Period	Group				𝑃^∗	(𝑃inter)
		Placebo group (𝑁=55)		TJ001 group (𝑁=57)
		Mean ± S.D.	(𝑃intra)	Mean ± S.D.	(𝑃intra)
Weight, kg	Baseline	83.7±14.4	—	82.2±10.5	—	0.5458	—
	week 4	83.2±14.8		80.9±10.2		0.3272
	week 8	82.7±13.8		80.7±10.3		0.3900
	week 12	82.8±15.1		80.3±10.5		0.3080
	Δ0–12	−0.88±3.05	0.0371	−1.95±3.35	<0.0001	—	0.0708
	ANOVA	visit X group interaction: 𝑃=0.0816
Body mass index (BMI), kg/cm^2	Baseline	31.9±3.80	—	31.8±2.60	—	0.8598	—
	week 4	31.6±3.90		31.2±2.60		0.5660
	week 8	31.4±3.90		31.2±2.80		0.7407
	week 12	31.4±4.10		31.0±2.80		0.5420
	Δ0–12	−0.45±1.17	0.0061	−0.75±1.27	<0.0001	—	0.1680
	ANOVA	visit X group interaction: 𝑃=0.3703
Waist circumference (WC), cm	Baseline	100.4±9.50	—	99.6±7.00	—	0.6259	—
	week 4	99.7±9.60		97.6±7.40		0.1932
	week 8	98.6±9.30		97.3±7.70		0.3938
	week 12	97.3±11.70		96.3±7.90		0.6056
	Δ0–12	−3.09±8.57	0.010	−3.29±4.54	<0.0001	—	0.7665
	ANOVA	visit X group interaction: 𝑃=0.4725
Hip circumference (HC), cm	Baseline	110.4±8.80	—	109.9±6.00	—	0.7096	—
	week 4	109.8±8.30		108.4±5.70		0.3027
	week 8	109.2±8.40		108.1±5.50		0.4026
	week 12	108.6±8.30		107.6±5.70		0.4330
	Δ0–12	−1.82±3.48	0.0003	−2.35±3.51	<0.0001	—	0.3183
	ANOVA	visit X group interaction: 𝑃=0.3456
Waist/hip ratio (WHR)	Baseline	0.91±0.05	—	0.90±0.05	—	0.6934	—
	week 4	0.91±0.05		0.90±0.05		0.4217
	week 8	0.90±0.04		0.90±0.06		0.6775
	week 12	0.90±0.05		0.89±0.05		0.4159
	Δ0–12	−0.0073±0.04	0.1307	−0.0114±0.03	0.0108	—	0.4058
	ANOVA	visit X group interaction: 𝑃=0.7758

𝑃^∗: A 𝑃 value for between-group comparison at each visit and visit X group interaction using ANOVA.
(𝑃_intra): A 𝑃 value for within-group comparison between baseline and 5th visit by paired 𝑡-test.
(𝑃_inter): A 𝑃 value for between-group comparison after 12-week treatment using ANCOVA (baseline as covariate).
Δ0–12: Changes between baseline and the 5th visit (after 12-week treatment).
𝑃<0.05 were considered statistically significant.